The DOI matches its Crossref record; 159 of the 161 references it cites were found in a registry or an index.
Immunomodulation by anticancer cell cycle inhibitors
Open accessAbstract
Cell cycle proteins that are often dysregulated in malignant cells, such as cyclin-dependent kinase 4 (CDK4) and CDK6, have attracted considerable interest as potential targets for cancer therapy. In this context, multiple inhibitors of CDK4 and CDK6 have been developed, including three small molecules (palbociclib, abemaciclib and ribociclib) that are currently approved for the treatment of patients with breast cancer and are being extensively tested in individuals with other solid and haematological malignancies. Accumulating preclinical and clinical evidence indicates that the anticancer activity of CDK4/CDK6 inhibitors results not only from their ability to block the cell cycle in malignant cells but also from a range of immunostimulatory effects. In this Review, we discuss the ability of anticancer cell cycle inhibitors to modulate various immune functions in support of effective antitumour immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Accumulating evidence suggests that CDK4/CDK6 inhibitors, as well as inhibitors of other CDKs, do not only arrest the proliferation of malignant cells, they also mediate multipronged immunomodulatory effects (Klein et al., 2018; Petroni et al., 2020)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Petroni et al., 2020
In the citing paper
“various CDK4/CDK6 inhibitors have been shown to mediate a variety of immunostimulatory effects by directly interacting with immune cells (Petroni et al., 2020).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Petroni et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Self-citationThe p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J., Lanier, L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 3,272
Cellular Senescence: Defining a Path Forward
Gorgoulis, V., Adams, P. D., Alimonti, A., Bennett, D. C., Bischof, O., Bishop, C., Campisi, J., Collado, M., Evangelou, K., Ferbeyre, G., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.005 · Cited by 3,225
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
Innate or adaptive immunity? The example of natural killer cells
Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011) · Science · doi:10.1126/science.1198687 · Cited by 2,824
Cited by
Sorted by citations
Items 101–163 of 163
Li, F., Liu, Z.-H., Huang, K., Ding, S., Zhu, C., Fu, Y., Sun, X., Zhang, S., Zhang, R., Jiang, Z., et al. (2025) · Journal of Cancer · doi:10.7150/jca.101892 · Cited by 2
Jiang, C., Chen, K., Li, D., Hu, S., & Jin, Q. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118271 · Cited by 2
Advances in the Synthesis Process of Antitumor Drugs CDK4/6 Inhibitors
Li, J., Gao, F., & Zhang, W. (2026) · Chinese Journal of Organic Chemistry · doi:10.6023/cjoc202509021 · Cited by 2
Ma, C., Ji, X., Huang, W., Guo, S., Wang, L., Wu, X., Zheng, H., & Wang, J. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00005 · Cited by 2
Chen, L., Liu, Y., Zhu, N., Xie, H., Zhu, T., Duan, Q., Zhang, L., Liu, Z., Zhou, X. Y., & Tong, J. (2026) · APOPTOSIS · doi:10.1007/s10495-026-02381-4 · Cited by 2
Baclig, N. V., Chengappa, M., Soliman, A. J., Jacob, S., LeVee, A. A., Fisch, S. C., Face, C., Chaudhry, S., Idossa, D. W., Poonacha, T., et al. (2026) · Clinical Breast Cancer · doi:10.1016/j.clbc.2026.07.026 · Cited by 2
Evaluating the Therapeutic Effect of Hispidin on Prostate Cancer Cells
Chan, K.-C., Basavaraj, P., Tsai, J.-C., Viehoever, J., Hsieh, B.-Y., Li, X., Huang, G., & Huang, W. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147857 · Cited by 2
Hong, C.-E., & Lyu, S. (2025) · Biocell · doi:10.32604/biocell.2025.061334 · Cited by 2
Genetic variant within CDK6 regulates immune response to palbociclib treatment
Serra, V., Orrù, V., Steri, M., Fiorillo, E., Cucca, F., & Żołędziewska, M. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108777 · Cited by 2
Cytofluorometric assessment of cell cycle progression in irradiated cells
Jiménez‐Cortegana, C., Klapp, V., Bloy, N., Galassi, C., Sato, A., Yamazaki, T., Buqué, A., Galluzzi, L., & Petroni, G. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2021.12.025 · Cited by 2
Self-citationKlapp, V., Bloy, N., Jiménez‐Cortegana, C., Buqué, A., & Petroni, G. (2023) · Methods in cell biology · doi:10.1016/bs.mcb.2023.02.018 · Cited by 1
Self-citationSelective CDK4 inhibition holds promise for breast cancer
Beltrán‐Visiedo, M., Shulman, R. M., & Galluzzi, L. (2025) · Cell Research · doi:10.1038/s41422-025-01117-4 · Cited by 1
Self-citationÖnder, T., Öner, İ., Karaçin, C., & Ateş, Ö. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02770-w · Cited by 1
Germline BRCA2 mutations foster resistance to CDK4/6 inhibitors in breast cancer
Bolini, L., Naulin, F., Johnson, N., & Galluzzi, L. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01481-3 · Cited by 1
Self-citationCell cycle dysregulation: a central hub in colitis-associated colorectal carcinogenesis
Fu, Y., Wang, Y., Wu, S., Ying, Y., Li, J. N., Ou, Y., Wang, Y., Li, L., Wu, Y., Yan, J., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1775221 · Cited by 1
CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities
Chinea, L. E., Hauer, C., Pal, K., Chang, H. L., & Chan, I. S. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01232-1 · Cited by 1
Caspase 2 and p53 Reunited in Tumor Control
Petroni, G., Vitale, I., & Galluzzi, L. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.09.001 · Cited by 1
Self-citationLin, Y.-J., Huang, C.-Y., Shen, Y., Wei, K., Chuang, C., Hsu, P., Huang, Y.-C., Hwang, T., & Chen, P. (2022) · PubMed Central · Cited by 1
Radiation therapy: An old dog learning new tricks
Sato, A., Kraynak, J., Marciscano, A. E. E., & Galluzzi, L. (2022) · Methods in cell biology · doi:10.1016/s0091-679x(22)00139-x · Cited by 1
Self-citationKolyadina, I. V. (2024) · Tumors of female reproductive system · doi:10.17650/1994-4098-2024-20-1-89-103 · Cited by 1
Bibliometrics analysis of IL-27 as a unique cytokine (2002–2023) and impact on cancer progression
Shi, N., Xia, X., Chen, Y., Ye, Y., Tang, X., & Li, Z. (2024) · Aging Research · doi:10.26599/agr.2024.9340033 · Cited by 1
An immunological mechanism of resistance to CDK4/6 inhibitors in HR + breast cancer
Galassi, C., Petroni, G., Knott, S., & Galluzzi, L. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2520269 · Cited by 1
Self-citationNUF2 Correlates with Poor Prognosis in Non-Small Cell Lung Cancer: A Systematic Multi-Omics AnalysisPreprint
Chen, M., Zhang, Y., Liang, Y., Luo, D., & Wang, W. (2020) · doi:10.21203/rs.3.rs-52844/v1
Saavedra, C., Vallejo, A., Longo, F., Domingo, J. J. S., Fernández, M., Gión, M., López-Miranda, E., Martínez-Jáñez, N., Guerra, E., Chamorro, J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-798329/v1
Sahu, A. D., Wang, X., Munson, P. B., Klomp, J. P. G., Wang, X., Gu, S. S., Qian, G., Nicol, P. B., Zeng, Z., Wang, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.25.465724
Philadelphia-negative myeloproliferative neoplasms: From origins to new perspectives
Bartalucci, N., & Galluzzi, L. (2021) · International review of cytology · doi:10.1016/s1937-6448(21)00127-1
Self-citationLiu, M., Fang, Q., Huang, Y., Zhou, J., & Wang, Q. (2021) · Research Square · doi:10.21203/rs.3.rs-1069383/v1
Philadelphia-negative myeloproliferative neoplasms: From origins to new perspectives
Bartalucci, N., & Galluzzi, L. (2022) · International review of cytology · doi:10.1016/s1937-6448(22)00019-3
Self-citationSaavedra, C., Vallejo, A., Longo, F., Domingo, J. J. S., Fernández-Abad, M., Gión, M., López-Miranda, E., Martínez-Jáñez, N., Guerra, E., Chamorro, J., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1862721/v1
Saavedra, C., Vallejo, A., Longo, F., Domingo, J. J. S., Fernández-Abad, M., Gión, M., López-Miranda, E., Martínez-Jáñez, N., Guerra, E. M., Chamorro, J., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1862721/v2
Emergent impact of lifestyle on tumor progression and response to therapy
Buqué, A., Montrose, D. C., & Galluzzi, L. (2022) · International review of cytology · doi:10.1016/s1937-6448(22)00132-0
Self-citation1144 IL17-producing γδ T cells promote resistance to CDK4/6 inhibitors in HR+HER2- breast cancer
Petroni, G., Gouin, K. H., Galassi, C., Buqué, A., Bloy, N., Yamazaki, T., Sato, A., Jiménez‐Cortegana, C., Kirchmair, A., Massa, C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-sitc2022.1144
Self-citationRadiation therapy: An old dog learning new tricks
Sato, A., Kraynak, J., Marciscano, A. E. E., & Galluzzi, L. (2023) · Methods in cell biology · doi:10.1016/s0091-679x(23)00036-5
Self-citationPetroni, G., Buqué, A., Yamazaki, T., Bloy, N., Liberto, M. D., Chen‐Kiang, S., Formenti, S. C., & Galluzzi, L. (2023) · doi:10.1158/1078-0432.c.6530411.v1
Self-citationPetroni, G., Buqué, A., Yamazaki, T., Bloy, N., Liberto, M. D., Chen‐Kiang, S., Formenti, S. C., & Galluzzi, L. (2023) · doi:10.1158/1078-0432.c.6530411
Self-citationSahu, A. D., Wang, X., Munson, P. B., Klomp, J. P. G., Wang, X., Gu, S. S., Han, Y., Qian, G., Nicol, P. B., Zeng, Z., et al. (2023) · doi:10.1158/2159-8290.22543005
Radiation therapy: An old dog learning new tricks
Sato, A., Kraynak, J., Marciscano, A. E. E., & Galluzzi, L. (2023) · Methods in cell biology · doi:10.1016/s0091-679x(23)00166-8
Self-citationImmune Gene Signature as a Predictor of CDK4/6 Inhibitor Response in HR+/HER2– Breast CancerPreprint
Felip, E., García-Vidal, E., Heras, S. C. L., Bernat‐Peguera, A., Cirauqui, B., Bergamino, M. A., Quiroga, V., Teruel, I., Ferrando‐Díez, A., Pous, A., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6129690/v1
Current progress in targeting mitotic kinases in PDAC
Barlow, T. M. A., Rooman, I., & Ballet, S. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00162e
Kolyadina, I. V. (2025) · Tumors of female reproductive system · doi:10.17650/1994-4098-2025-21-2-47-59
Титов, К. С., Аполлонович, К. Д., Kuts, I. N., Lebedev, S. S., Греков, Д. Н., & Lorie, Z. V. (2025) · P A Herzen Journal of Oncology · doi:10.17116/onkolog20251405189
Wu, Y., Shrestha, P., Heape, N. M., & Yarchoan, R. (2022) · Figshare · doi:10.6084/m9.figshare.19766319
Li, Z., Fu, R., Wen, X., & Zhang, L. (2023) · Figshare · doi:10.6084/m9.figshare.22600690
Klapp, V., Buqué, A., Bloy, N., Sato, A., Yamazaki, T., Zhou, X. K., Formenti, S. C., Galluzzi, L., & Petroni, G. (2024) · Figshare · doi:10.6084/m9.figshare.26567786
Self-citationWu, Y., Shrestha, P., Heape, N. M., & Yarchoan, R. (2022) · Figshare · doi:10.6084/m9.figshare.19766322
Wu, Y., Shrestha, P., Heape, N. M., & Yarchoan, R. (2022) · Figshare · doi:10.6084/m9.figshare.19766325
Klapp, V., Buqué, A., Bloy, N., Sato, A., Yamazaki, T., Zhou, X. K., Formenti, S. C., Galluzzi, L., & Petroni, G. (2024) · Figshare · doi:10.6084/m9.figshare.26567783
Self-citationWu, Y., Shrestha, P., Heape, N. M., & Yarchoan, R. (2022) · Figshare · doi:10.6084/m9.figshare.19766331
Wu, Y., Shrestha, P., Heape, N. M., & Yarchoan, R. (2022) · Figshare · doi:10.6084/m9.figshare.19766310
Wu, Y., Shrestha, P., Heape, N. M., & Yarchoan, R. (2022) · Figshare · doi:10.6084/m9.figshare.19766316
Wu, Y., Shrestha, P., Heape, N. M., & Yarchoan, R. (2022) · Figshare · doi:10.6084/m9.figshare.19766328
Dawoud, A., Youness, R. A., Nafea, H., Manie, T., Bourquin, C., Szabo, C., Abdel-Kader, R. M., & Gad, M. Z. (2024) · Figshare · doi:10.6084/m9.figshare.26707628
Wu, Y., Shrestha, P., Heape, N. M., & Yarchoan, R. (2022) · Figshare · doi:10.6084/m9.figshare.19766313
Park, J., Ahn, H. K., Kim, H. R., Kim, S., Park, K., Yun, T., Kim, H. J., Lee, S., Cho, S. H., Park, S., et al. (2026) · Head & Neck · doi:10.1002/hed.70165
Yang, Z., & Song, H. (2026) · Molecular Immunology · doi:10.1016/j.molimm.2026.01.014
Lagarce, L., Gaiffe, A., Freppel, R., Storck, W., Cracowski, J., & Briet, M. B. (2026) · Therapies · doi:10.1016/j.therap.2026.03.005
Pyridine-based derivatives as emerging scaffolds for immunomodulatory drug development
Talukdar, S. K., Bhuyan, R., Das, T., Talukdar, S., Dasgupta, D., Sahariah, B. J., Talukdar, A., Patowary, P., Ansary, A., Mazumder, M. U., et al. (2026) · Discover Chemistry. · doi:10.1007/s44371-026-00783-6
Li, N., Jiang, S., Ding, Z., Ju, W., Zhang, F., Mu, D., Yu, S., & Lin, L. (2026) · Immuno · doi:10.3390/immuno6030053
Zheng, S., Shen, Z., Wu, Y., Huang, X., Zhang, Z., Liu, J., Wei, Q., Chen, W., Chen, Y., & Xu, L. (2026) · MedComm · doi:10.1002/mco2.70898
Liu, K., Zhu, Y., & Zhu, H. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2619281
Bolini, L., Coffelt, S. B., Silva‐Santos, B., Wiest, D. L., & Galluzzi, L. (2026) · Journal of Clinical Investigation · doi:10.1172/jci209159
Self-citation
Metadata
- Authors
- Petroni, G., Formenti, S. C., Chen-Kiang, S., & Galluzzi, L.
- Affiliations
- Weill Cornell Medicine (US)
- Université Paris Cité (FR)
- Corresponding author
- Galluzzi, Lorenzo
- Venue
- Nature Reviews Immunology
- Published
- 2020-04-28
- Volume
- 20
- Issue
- 11
- Pages
- 669-679
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- PMC
- PMC7584736
- OpenAlex
- W3020753817
- Cited by
- 163
- References
- 161
- Citations by year
- 2026: 17 · 2025: 22 · 2024: 22 · 2023: 26 · 2022: 45 · 2021: 20 · 2020: 11
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Funders
- National Cancer Institute (R01CA188794, P01CA214274)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CDK4/6 inhibitors, immunomodulation, antitumor immunity, cell cycle inhibitors, palbociclib, abemaciclib, ribociclib, breast cancer, cyclin-dependent kinases, tumor immunology
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Cell Cycle, Clinical Trials as Topic, Humans, Neoplasms, Cell Cycle Proteins, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Immunomodulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
